Spero Therapeutics, Inc. (SPRO) AI Dilution Summary

Estimated cash was $153,728,231 as of 2026-07-08, rolled forward from $50,774,000 at the 2026-06-30 balance-sheet date against estimated monthly burn of $1,785,000. On 2026-07-08 the company raised $103,425,000 net in a non-dilutive royalty-backed financing with affiliates of HealthCare Royalty (HCRx), through senior secured notes sold by its subsidiary Spero SPV, LLC. Its at-the-market program with Jefferies LLC is active and authorised to $100,000,000.